Doliver Advisors LP Lowers Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Doliver Advisors LP reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 8.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 74,328 shares of the biotechnology company’s stock after selling 6,672 shares during the period. Doliver Advisors LP’s holdings in BioCryst Pharmaceuticals were worth $559,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,322 shares during the last quarter. Xponance Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 13.1% during the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,505 shares during the last quarter. Captrust Financial Advisors grew its position in shares of BioCryst Pharmaceuticals by 19.4% during the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 2,644 shares in the last quarter. Creative Planning increased its holdings in shares of BioCryst Pharmaceuticals by 5.9% in the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock worth $375,000 after purchasing an additional 2,734 shares during the last quarter. Finally, SkyView Investment Advisors LLC lifted its position in shares of BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after buying an additional 3,000 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Barclays upped their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.60.

BioCryst Pharmaceuticals Stock Up 2.9 %

BioCryst Pharmaceuticals stock traded up $0.22 during midday trading on Monday, reaching $7.92. The stock had a trading volume of 916,186 shares, compared to its average volume of 1,753,659. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -12.98 and a beta of 1.76. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $8.88. The company has a fifty day moving average of $7.61 and a 200 day moving average of $7.53.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same period in the prior year, the company posted ($0.19) EPS. The company’s quarterly revenue was up 35.1% compared to the same quarter last year. Equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.